Study Details
Design, interventions, and primary outcomes
About This Study
This study is a prospective evaluation of systemic, intravenous high-dose methotrexate (HD-MTX, 8 g/m2) in patients with triple negative, HER2-positive, and hormone refractory breast cancer with leptomeningeal metastasis (LMD) with or without brain parenchymal involvement.
Design
Interventions / Regimen
- Drug: High-dose Methotrexate (8 gm/m2; HD-MTX) — Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (\~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.
Primary Outcomes
- Overall Survival (at 12 weeks) (12 weeks)
Phase: PHASE2
Status: Recruiting
Start Date: 2015-05
Completion: 2027-07
Sex: ALL
Volunteers: false
Enrollment: 16 (ESTIMATED)
Collaborators: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI)
- Roy Strowd, MD (PRINCIPAL_INVESTIGATOR) - Wake Forest University Health Sciences
- Drug: High-dose Methotrexate (8 gm/m2; HD-MTX) — Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (\~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.